Division of Hematologic Malignancies 1 (DHM1)
The Division of Hematologic Malignancies 1 (DHM1) manages Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologic Licensing Applications (BLAs) for:
- Acute leukemias and myelodysplastic syndromes
- Chronic myeloid leukemia and other myeloid neoplasms
- Supportive care drugs for stem cell transplantation, including for acute and chronic graft-vs-host diseases (GVHD)
- Supportive care drugs for immune effector cell therapies, including cytokine release syndrome (CRS)
Mailing Address
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Hematologic Malignancies 1 (DHM1)
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-4969
Fax: (301) 837-6142